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Abstract
Here we discuss the report by Claassen and colleagues describing an indirect treatment comparison between
tetrabenazine and deutetrabenazine for chorea in Huntington’s disease using individual patient data. We note the
potential for discrepancies in apparently statistically significant findings, due to the rank reversal phenomenon. We
provide some cautionary observations and suggestions concerning the limitations of indirect comparisons and the low
likelihood that good quality evidence will become available to guide clinical decision comparing these two agents.
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To the Editor,
We read with interest the report by Claassen and
colleagues describing an indirect treatment comparison
between tetrabenazine (TBZ) and deutetrabenazine (DEU)
for chorea in Huntington’s disease (HD) using individual
patient data [1].
DEU is a form of TBZ, chemically-modified to optimize
its pharmacokinetic properties. Both are vesicular
monoamine transporter 2 (VMAT2) inhibitors and each
was tested successfully against placebo for chorea associ-
ated with HD [2, 3]. No double-blinded head-to-head
comparison has been performed or is planned to compare
the efficacy and safety profiles of these compounds.
Indirect treatment comparisons are useful meta-research
tools when little or no data directly comparing treatment
are available [4]. In meta-research, the use of individual
patient data instead of aggregate data has many potential
advantages, such as the power to study subgroups and to
control for confounding factors. To some extent Claassen
et al. used individual patient data, since raw patient data
from the FIRST-HD trial testing DEU was incorporated
into the analysis. This partially overcomes possible report-
ing bias from the literature, such as adverse events frequen-
cies not recorded in primary reports, and provides the
opportunity to use more complex and complete statistical
models adjusted to important covariates. It is a shame that
individual patient data from the TETRA-HD trial [3] were
not included, especially since both trials were performed by
the same study consortium (the Huntington Study Group).
In addition, it would have been both possible and interest-
ing to undertake exploratory analyses to find out whether
subgroups of patients with different genders, CAG repeat
lengths, baseline levels of functional ability, motor symp-
toms and quality of life differed in regards to safety profile.
We also think it unfortunate that the authors limited
their report to safety data, while it would be extremely
relevant to learn how the efficacy profiles of TBZ and
DEU compared using the individual patient data available
to them. We recently performed an indirect treatment
comparison using all published aggregate data from the
same trials, and found no difference between the primary
efficacy outcomes of both trials: the total maximal chorea
score change from baseline mean difference was between
TBZ and DEU was −1.00 (95% confidence interval: −3.04
to 1.04) [5].
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Interestingly, in contrast to Claasen and co-authors’
findings, our safety outcomes did not demonstrate any
difference between odds ratios of TBZ over DEU
(Table 1). However, when converting our raw dataset to
risk differences instead of odds ratios, as presented by
Claassen et al., our results were in line with theirs, in
regards to direction and magnitude of effect. This is a
well-described statistical phenomenon called rank rever-
sal. It stems from the fact that different measures (e.g.
risk differences, risk ratios, and odds ratios) are affected
differently by dissimilar baseline risks [6]. Bucher’s
model of indirect treatment comparisons was originally
designed for odds ratios, but others have applied it to
risk ratios and risk differences, with proper adjustment.
When indirectly comparing treatments, the choice of
presented metric matters. We believe it is important for
readers to be made aware of the potential for apparently
discrepant findings that may arise from the rank reversal
phenomenon [6]. Undoubtedly, risk differences increase in-
terpretability, but odds ratios are the only measure that
guarantees the avoidance of impossible predicted event
rates when extrapolating the results for real populations
(for example, applying a risk difference of 0.1 to a popula-
tion with a risk of 0.05 would give rise to an apparent popu-
lation risk with a value less than zero, which is implausible)
and relative measures are known to be more consistent
than absolute measures [7–9].
Choice of data and outcomes aside, an overarching
concern is that none of the included clinical trials has been
appropriately powered to investigate the safety of these
compounds, and an indirect treatment comparison of one
trial per agent (i.e. TBZ versus placebo, and DEU versus
placebo), cannot improve the precision of the results.
Therefore, the results of these comparisons [1, 5] should be
interpreted with caution; and although regarded as best
available evidence, they are nonetheless of low quality
according to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) framework [10].
Given all this, only a direct comparison between TBZ
and DEU would be able to rigorously test whether the
efficacy profiles of these compounds significantly differ, and
our sample size calculation (over 600 participants) suggests
that such a trial is unlikely to take place [5]. Further post-
authorisation safety studies or other observational studies
will be required to provide robust evidence on the safety
profile of DEU to inform safe prescribing decisions.
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Table 1 Indirect treatment comparison between TBZ and DEU (as reported by us in Rodrigues et al. [5]), both in odds ratios as











SAE 5.44 (0.09 to 322.08) −0.07 (−0.17 to 0.03) −0.074 (−0.167 to 0.019)
Somnolence 4.95 (0.34 to 72.37) −0.21 (−0.39 to −0.03)* −0.215 (−0.392 to −0.037)*
Diarrhoea 0.07 (0.03 to 2.06) 0.12 (−0.03 to 0.27) 0.115 (−0.038 to 0.268)
Insomnia 14.18 (0.47 to 426.77) −0.24 (−0.40 to −0.04)* −0.237 (−0.387 to −0.087)*
Fatigue 1.21 (0.31 to 11.14) −0.07 (−0.26 to 0.12) −0.067 (−0.256 to 0.123)
Falls 2.71 (0.31 to 23.98) −0.07 (−0.26 to 0.12) −0.078 (−0.265 to 0.110)
Depression 17.15 (0.55 to 531.90) −0.17 (−0.31 to −0.28)* −0.170 (−0.304 to −0.037)*
Presentation as risk differences produces statistically significant differences between DEU and TBZ that are not seen when presented as odds ratios; neither
approach is intrinsically more accurate and an awareness of the difference is important. TBZ, tetrabenazine; DEU, deutetrabenazine; OR, odds ratio; 95% CI, 95%
confidence interval; RD, risk difference; SAE, severe adverse events; *p-value < 0.05
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